Answer: Delayed Institutional, Administrative and Regulatory Approval. Complexity of Cancer, Tumor Heterogeneity and Immune Escape. Limited Availability of Reagents for Combination Immunotherapy Studies. Limited Funds Available to Translate Science into Patients
Explanation:
